Skip to main content

Table 3 Interview responses part 3

From: Case studies for implementing MCDA for tender and purchasing decisions in hospitals in Indonesia and Thailand

  Thailand hospital tender (n = 4) Indonesia hospital drug purchasing (n = 4)
Accelerators (number of mentions) Education in evaluation techniques [3]
National policy [3]
Support/advice [1]
Clarity of criteria [1]
Simple Tools [1]
Training [3]
Leadership support [2]
Practical experience [1]
Association support (Medical and Hospital) [1]
Using local hospital data [1]
Solve conflicts in interest [1]
Access to data [1]
Inhibitors (number of mentions) Complexity of assessing criteria (all 4)
Resistance to change [2]
Lack of scoring definition [1]
Subjectivity of some criteria [1]
Practice integration [1]
Need for training [1]
Lack of training and knowledge [3]
Conflicts with current process [2]
Industry rejection [1]
Complexity of MCDA process [1]
Stakeholders (the ones who were involved are in bold type fonts; the other were also mentioned as important) Academic pharmacists
Hospital pharmacists
Head of hosp. pharmacy
Head of specialty department for PTC
Director of hospital
Procurement pharmacists
Pharmaceutical industry
Academic leaders
Hospital director
Hospital administration
Pharmacists (supply manager)
Therapeutic committee
Hospital association
National Agency of Drug and Food Control of Republic of Indonesia
Pharmaceutical companies
Financial and legal department of hospital
Patient organization
Potential role of PAGs/POs Advocate for the importance of product quality and high-quality products
Increase awareness for the issue
Patient consensus on criteria
Analysis of patient experiences to create awareness for issue
Concern: potential lack of objectivity
  1. MCDA Multi-Criteria Decision Analysis, MoH   Ministry of Health, PAG Patient Advocacy Group, PO Patient Organization, PTC Pharmacy and Therapeutics Committee
  2. Summary of interview responses relating to accelerators or inhibitors observed in the implementation project so far and the potential role of patient advocacy groups (PAGs)